Merrimack Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $12.26
- Today's High:
- $12.42
- Open Price:
- $12.265
- 52W Low:
- $3
- 52W High:
- $13.66
- Prev. Close:
- $12.26
- Volume:
- 22836
Company Statistics
- Market Cap.:
- $175.58 million
- Book Value:
- 1.329
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-9100000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -8.45%
- Return on Equity TTM:
- -9.78%
Company Profile
Merrimack Pharmaceuticals Inc had its IPO on 2012-03-29 under the ticker symbol MACK.
The company operates in the Healthcare sector and Biotechnology industry. Merrimack Pharmaceuticals Inc has a staff strength of 0 employees.
Stock update
Shares of Merrimack Pharmaceuticals Inc opened at $12.27 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $12.26 - $12.42, and closed at $12.36.
This is a +0.82% increase from the previous day's closing price.
A total volume of 22,836 shares were traded at the close of the day’s session.
In the last one week, shares of Merrimack Pharmaceuticals Inc have increased by +0.98%.
Merrimack Pharmaceuticals Inc's Key Ratios
Merrimack Pharmaceuticals Inc has a market cap of $175.58 million, indicating a price to book ratio of 11.9369 and a price to sales ratio of 0.
In the last 12-months Merrimack Pharmaceuticals Inc’s revenue was $0 with a gross profit of $-9100000 and an EBITDA of $-2784000. The EBITDA ratio measures Merrimack Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Merrimack Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -8.45% with a return of equity of -9.78%.
In Q2, Merrimack Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Merrimack Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0.07
Its diluted EPS in the last 12-months stands at $-0.11 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0.07. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Merrimack Pharmaceuticals Inc’s profitability.
Merrimack Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -70.7575. Its price to sales ratio in the trailing 12-months stood at 0.
Merrimack Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 57.71% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $19.45 million
- Total Liabilities
- $411000.00
- Operating Cash Flow
- $-8811000.00
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Merrimack Pharmaceuticals Inc ended 2024 with $19.45 million in total assets and $0 in total liabilities. Its intangible assets were valued at $19.45 million while shareholder equity stood at $19.04 million.
Merrimack Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $411000.00 in other current liabilities, 1343000.00 in common stock, $-548298000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.13 million and cash and short-term investments were $18.97 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Merrimack Pharmaceuticals Inc’s total current assets stands at $19.44 million while long-term investments were $0 and short-term investments were $8.84 million. Its net receivables were $0 compared to accounts payable of $80000.00 and inventory worth $0.
In 2024, Merrimack Pharmaceuticals Inc's operating cash flow was $-8811000.00 while its capital expenditure stood at $0.
Comparatively, Merrimack Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $12.36
- 52-Week High
- $13.66
- 52-Week Low
- $3
- Analyst Target Price
- $4
Merrimack Pharmaceuticals Inc stock is currently trading at $12.36 per share. It touched a 52-week high of $13.66 and a 52-week low of $13.66. Analysts tracking the stock have a 12-month average target price of $4.
Its 50-day moving average was $12.05 and 200-day moving average was $12.01 The short ratio stood at 13.48 indicating a short percent outstanding of 0%.
Around 120.8% of the company’s stock are held by insiders while 5289.8% are held by institutions.
Frequently Asked Questions About Merrimack Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.